MedPath

T2* MRI Analysis for Sarcoma

Not Applicable
Completed
Conditions
Radiotherapy
Sarcoma
Magnetic Resonance Imaging
Registration Number
NCT03658343
Lead Sponsor
Bryan Allen
Brief Summary

T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • pathologically confirmed Sarcoma, by biopsy or excision
  • prescribed radiation therapy as per standard of care
  • treatment to begin within 5 weeks after surgery or biopsy
  • ECOG 0, 1, or 2
  • ability and willingness to provide informed consent
Exclusion Criteria
  • < 18 years of age

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in ferric iron levels detected by T2* MRIbaseline and 8 weeks

Change from baseline in Fe3+ iron levels

Secondary Outcome Measures
NameTimeMethod
Change in ferrous iron levels detected by T2* MRIBaseline and 8 weeks

Change from baseline in Fe2+ iron levels

Trial Locations

Locations (1)

Holden Comprehensive Cancer Center

🇺🇸

Iowa City, Iowa, United States

Holden Comprehensive Cancer Center
🇺🇸Iowa City, Iowa, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.